CClinicalTrials.gg
CompletedNCT04793334Slim-OSAUpdated Feb 27, 2026

Underlying Mechanisms of Obesity-induced Obstructive Sleep Apnea

An observational study in Obstructive Sleep Apnea and Obesity, sponsored by Brandon Nokes. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Brandon Nokes · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
106
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Obesity is a common risk factor for the development of obstructive sleep apnea. However, not all subjects with obesity develop obstructive sleep apnea. This study will attempt to determine the mechanistic drivers between obesity and obstructive sleep apnea.

Read the detailed description

Obstructive sleep apnea (OSA) is a highly prevalent disease with major neurocognitive and cardiovascular sequelae. Obesity is a major risk factor for OSA, but the underlying mechanisms remain unclear. Given the rising prevalence of obesity and the lack of adequate therapies for some afflicted patients, further mechanistic work is clearly required. Bariatric surgery is being done increasingly with compelling outcome data emerging; however, clinical response to weight loss is highly variable. In some patients, OSA is not present at baseline, despite morbid obesity, in other patients, OSA resolves following bariatric surgery, while other patients have persistence of OSA despite weight loss, and still other patients can experience re-emergence of OSA in long term follow-up studies after bariatric surgery. OSA can occur due to several major pathophysiological factors including pharyngeal anatomy, pharyngeal dilator muscle dysfunction, unstable ventilatory control, end- expiratory lung volume and arousal threshold. As a result considerable complexity exists in the obesity/OSA relationship, suggesting the need for further research. First, the investigators will perform a baseline evaluation of pathophysiological traits among obese people prior to weight loss surgery. Because some people will have OSA and some will not, the investigators will define the potential mechanisms underlying OSA and potential protective mechanisms among obese people without OSA (pharyngeal critical closing pressure Pcrit primary outcome). Second, the investigators will re-evaluate these same individuals from the standpoint of sleep study and pathophysiological traits six months following bariatric surgery after a variable degree of weight loss. The investigators anticipate that some OSA patients will have resolution of OSA whereas others will have persistence of disease. For non-OSA patients undergoing weight loss, the investigators will have a positive control group which will allow the investigators to account for non-specific effects of weight loss. This aim will allow the investigators to test the hypothesis that pharyngeal mechanics is the predominant mechanism whereby weight loss leads to improvement in OSA. Third, the investigators will perform magnetic resonance imaging during wakefulness at functional residual capacity, total lung capacity and residual volume on participants at baseline and 6months following bariatric surgery. This aim will allow the investigators to perform structure/function assessments in our participants, to define the impact of weight loss on pharyngeal anatomy, and to quantify the lung volume dependence of the upper airway before and after weight loss. The acquired data will also be used for computational modeling including dynamic assessment of pharyngeal function during tidal breathing. As a result of the proposed research, the investigators are confident that the investigators will gain major insights into the as yet unanswered question "why does obesity (sometimes) cause sleep apnea". This research will have major therapeutic implications as it will allow the investigators to individualize therapy for afflicted patients.

02

Conditions studied

  • Obstructive Sleep Apnea
  • Obesity
03

In context

Sleep Apnea, Obstructive

2,198 studies on the registry are indexed under Sleep Apnea, Obstructive; 469 are open to participants now.

This study's enrollment of 106 is close to the median of 104 across 648 observational studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

This is the only study on the registry with Brandon Nokes as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Noting the inclusion and exclusion criteria above, we aim to recruit 110 patients, anticipating 20% drop out and a final n of 90. Further, we aim for to recruit 60 participants with OSA and 30 participants without OSA.

Inclusion criteria

  • - Men and women
  • Ages >= 18-65 years old
  • BMI 35 kg/m2--and above
  • Scheduled for sleeve gastrectomy (bariatric surgery)

Exclusion criteria

Exclusion Criteria:

  • Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.
  • Pregnancy
  • Currently smoking
  • Any respiratory disorder other than OSA or well controlled asthma
  • contraindication to MRI
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
106 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Obese + OSA

    Inclusion Criteria: * Men and women * Ages \>= 18-65 years old * BMI 35 kg/m2-above * Scheduled for sleeve gastrectomy (bariatric surgery) * OSA identified by PSG Exclusion Criteria: * Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma. * Pregnancy * Currently smoking * Any respiratory disorder other than OSA or well controlled asthma * contraindication to MRI

    Procedure: sleeve gastectomy

  • Obese without OSA

    Inclusion Criteria: * Men and women * Ages \>= 18-65 years old * BMI 35kg/m2 and above * Scheduled for sleeve gastrectomy (bariatric surgery) * No OSA identified by PSG Exclusion Criteria: * Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma. * Pregnancy * Currently smoking * Any respiratory disorder other than OSA or well controlled asthma * contraindication to MRI

    Procedure: sleeve gastectomy

Interventions

  • Proceduresleeve gastectomy

    routine sleeve gastrectomy

06

What researchers measure

Primary outcomes

  1. muscle traits contributing to OSA in obesity - change is being assessed over time

    1\. To measure upper airway collapsibility as well as the other traits (e.g. muscle responsiveness) in both groups. The traits can be measured during sleep using our well-validated research method that mimics transient upper airway obstruction and importantly, assesses the individual's response to hypoventilation

    Time frame: Time point 1: Within 1 month of bariatric surgery, Time point 2: 6 months following bariatric surgery

  2. changes in pcrit after bariatric surgery

    2\. We will reassess obese people with and without OSA following major weight loss (bariatric surgery). This aim will allow us to test the hypothesis that patients who experience improvement in OSA will be those with the greatest improvement in upper airway mechanics (Pcrit). The obese people without OSA undergoing weight loss will be a positive control group, which will allow us to exclude non-specific effects of weight loss.

    Time frame: Time point 1: Within 1 month of bariatric surgery, Time point 2: 6 months following bariatric surgery

  3. MRI upper airway changes following bariatric surgery - change is being assessed over time

    3\. To determine the anatomic correlates of upper airway collapsibility in both groups using magnetic resonance imaging during natural sleep.

    Time frame: Time point 1: Within 1 month of bariatric surgery, Time point 2: 6 months following bariatric surgery

Secondary outcomes

  1. exploratory outcomes

    phlebotomy for ABG and transcriptomic assessments - change is being assessed over time

    Time frame: Time point 1: Within 1 month of bariatric surgery, Time point 2: 6 months following bariatric surgery

07

Study locations

1 site
  • UCSD - Altman Clinical Research Institute (ACTRI)
    La Jolla, California 92037, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04793334
Lead sponsor
Brandon Nokes
Responsible party
Brandon Nokes (Post-doctoral fellow, Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology, University of California, San Diego) — Sponsor-investigator
First posted
Mar 11, 2021
Start date
Mar 20, 2021
Primary completion
May 31, 2025
Completion
May 31, 2025
Last update
Feb 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion